Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial

The Lancet

Volumn 391, Issue 10128, 2018, Pages 1378-1390

  Sagara, Issaka ^a   Beavogui, Abdoul Habib ^b   Zongo, Issaka ^c   Soulama, Issiaka ^d   Borghini Fuhrer, Isabelle ^e   Fofana, Bakary ^a   Traore, Aliou ^a   Diallo, Nouhoum ^a   Diakite, Hamadoun ^a   Togo, Amadou H ^a   Koumare, Sekou ^a   Keita, Mohamed ^a   Camara, Daouda ^b   Somé, Anyirékun F ^c   Coulibaly, Aboubacar S ^d   Traore, Oumar B ^a   Dama, Souleymane ^a   Goita, Siaka ^a   Djimde, Moussa ^a   Bamadio, Amadou ^a   Dara, Niawanlou ^a   Maiga, Hamma ^a   Sidibe, Bouran ^a   Dao, Francois ^a   Coulibaly, Moctar ^a   Alhousseini, Mohamed Lamine ^a   Niangaly, Hamidou ^a   Sangare, Boubou ^a   Diarra, Modibo ^a   Coumare, Samba ^a   Kabore, Moïse J T ^d   Ouattara, San Maurice ^d   Barry, Aissata ^d   Kargougou, Désiré ^d   Diarra, Amidou ^d   Henry, Noelie ^d   Soré, Harouna ^d   Bougouma, Edith C ^d   Thera, Ismaila ^a   Compaore, Yves D ^c   Sutherland, Colin J ^f   Sylla, Malick Minkael ^b   Nikiema, Frederic ^c   Diallo, Mamadou Saliou ^b   Dicko, Alassane ^a   Picot, Stephane ^g   Borrmann, Steffen ^h,i   Duparc, Stephan ^e   Miller, Robert M ^j   Doumbo, Ogobara K ^a   Shin, Jangsik ^k   Gil, Jose Pedro ^l   Björkman, Anders ^l   Ouedraogo, Jean Bosco ^c   Sirima, Sodiomon B ^d   Djimde, Abdoulaye A ^a   more..

^a and Technologies of Bamako   (Mali)

^b Centre de formation et de recherche en santé rurale de Mafèrinyah   (Guinea)

^c Institut de Recherche en Sciences de la Sante   (Burkina Faso)

^d Burkina Faso   (Burkina Faso)

^e Switzerland   (Switzerland)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g CNRS   (France)

^h UNIVERSITY OF TÜBINGEN   (Germany)

ⁱ German Centre for Infection Research   (Germany)

^j Artemida Pharma   (United Kingdom)

^k Shin Poong Pharmaceutical Company   (South Korea)

^l KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE PLUS PYRONARIDINE; ASPARTATE AMINOTRANSFERASE; DIHYDROARTEMISININ PLUS PIPERAQUINE; AMODIAQUINE; AMODIAQUINE, ARTESUNATE DRUG COMBINATION; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; DIHYDROARTEMISININ; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; NAPHTHYRIDINE DERIVATIVE; PIPERAQUINE; PYRONARIDINE; QUINOLINE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; BRONCHITIS; BURKINA FASO; CHILD; CLINICAL OUTCOME; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GAMETOCYTE; GROUPS BY AGE; GUINEA; HUMAN; HYPERTRANSAMINASEMIA; INCIDENCE; INFANT; INTENTION TO TREAT ANALYSIS; LIVER TOXICITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA; MALE; MALI; MULTICENTER STUDY; NONHUMAN; PARASITE CLEARANCE; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PRIORITY JOURNAL; QT PROLONGATION; QTCF PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REINFECTION; RHINITIS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG COMBINATION; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; LONGITUDINAL STUDIES; MALARIA; MALE; NAPHTHYRIDINES; QUINOLINES; YOUNG ADULT;

EID: 85044526619     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)30291-5     Document Type: Article

References (40)

1. WHO. World Malaria Report, 2016. 2016, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/252038/1/9789241511711-eng.pdf?ua=1 (accessed Jan 22, 2017).
2. WHO. Guidelines for the treatment of malaria. 3rd edn., 2015, World Health Organization, Geneva http://www.who.int/malaria/publications/atoz/9789241549127/en/ (accessed Nov 17, 2016).
3. Sagara, I, Fofana, B, Gaudart, J, et al. Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact. Am J Trop Med Hyg 87 (2012), 50–56.
4. Ndiaye, JL, Faye, B, Gueye, A, et al. Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. Malar J, 10, 2011, 237.
5. Adjei, GO, Kurtzhals, JA, Rodrigues, OP, et al. Amodiaquine-artesunate vs artemether–lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J, 7, 2008, 127.
6. Ngasala, BE, Malmberg, M, Carlsson, AM, et al. Efficacy and effectiveness of artemether–lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis 52 (2011), 873–882.
7. Mavoko, HM, Nabasumba, C, da Luz, RI, et al. Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. Lancet Glob Health 5 (2017), e60–e68.
8. WHO. WHO policy recommendation: seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. 2012, World Health Organization, Geneva http://www.who.int/malaria/publications/atoz/smc_policy_recommendation_en_032012.pdf?ua=1 (accessed Jan 9, 2016).
9. Duparc, S, Borghini-Fuhrer, I, Craft, CJ, et al. Safety and efficacy of pyronaridine–artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malar J, 12, 2013, 70.
10. Kayentao, K, Doumbo, OK, Penali, LK, et al. Pyronaridine–artesunate granules versus artemether–lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J, 11, 2012, 364.
11. Poravuth, Y, Socheat, D, Rueangweerayut, R, et al. Pyronaridine–artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One, 6, 2011, e14501.
12. Rueangweerayut, R, Phyo, AP, Uthaisin, C, et al. Pyronaridine–artesunate versus mefloquine plus artesunate for malaria. N Engl J Med 366 (2012), 1298–1309.
13. Tshefu, AK, Gaye, O, Kayentao, K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine–artesunate compared with artemether–lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 375 (2010), 1457–1467.
14. Sagara, I, Beavogui, AH, Zongo, I, et al. Safety and efficacy of re-treatments with pyronaridine–artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis 16 (2016), 189–198.
15. Bassat, Q, Mulenga, M, Tinto, H, et al. Dihydroartemisinin–piperaquine and artemether–lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One, 4, 2009, e7871.
16. Grande, T, Bernasconi, A, Erhart, A, et al. A randomised controlled trial to assess the efficacy of dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One, 2, 2007, e1101.
17. Naing, C, Mak, JW, Aung, K, Wong, JY, Efficacy and safety of dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomised controlled studies. Trans R Soc Trop Med Hyg 107 (2013), 65–73.
18. Ratcliff, A, Siswantoro, H, Kenangalem, E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369 (2007), 757–765.
19. Smithuis, F, Kyaw, MK, Phe, O, et al. Efficacy and effectiveness of dihydroartemisinin–piperaquine versus artesunate–mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367 (2006), 2075–2085.
20. Smithuis, F, Kyaw, MK, Phe, O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 10 (2010), 673–681.
21. Valecha, N, Phyo, AP, Mayxay, M, et al. An open-label, randomised study of dihydroartemisinin–piperaquine versus artesunate–mefloquine for falciparum malaria in Asia. PLoS One, 5, 2010, e11880.
22. Four Artemisinin-Based Combinations Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med, 8, 2011, e1001119.
23. Bukirwa, H, Unnikrishnan, B, Kramer, CV, Sinclair, D, Nair, S, Tharyan, P, Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev, 3, 2014 CD006404.
24. Zani, B, Gathu, M, Donegan, S, Olliaro, PL, Sinclair, D, Dihydroartemisinin–piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev, 1, 2014 CD010927.
25. Akpaloo, W, Purssell, E, Does the use of dihydroartemisinin–piperaquine in treating patients with uncomplicated falciparum malaria reduce the risk for recurrent new falciparum infection more than artemether–lumefantrine?. Malar Res Treat, 2014, 2014, 263674.
26. Zongo, I, Dorsey, G, Rouamba, N, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether–lumefantrine, and dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 45 (2007), 1453–1461.
27. WHO. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. 2003, World Health Organization, Geneva http://www.who.int/malaria/publications/atoz/whohtmrbm200350/en/ (accessed Nov 17, 2016).
28. WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. 2008, World Health Organization, Geneva http://www.who.int/malaria/publications/atoz/9789241596305/en/ (accessed Nov 17, 2016).
29. Friedman, L, Furberg, C, DeMets, D, Fundamentals of clinical trials. 4th edn., 2010, Springer-Verlag, New York.
30. Sagara, I, Fofana, B, Sidibe, B, et al. Évaluation de l'effet de différentes combinaisons thérapeutiques à base d'artémisinine, sur l'incidence du paludisme dans une zone hyperendémique de paludisme au Mali. Rev Epidemiol Sante Publique, 58, 2010, S85.
31. Dama, S, Niangaly, H, Ouattara, A, et al. Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether–lumefantrine treatment in Mali. Malar J, 16, 2017, 59.
32. Amato, R, Lim, P, Miotto, O, et al. Genetic markers associated with dihydroartemisinin–piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. Lancet Infect Dis 17 (2017), 164–173.
33. Ahmed, T, Sharma, P, Gautam, A, et al. Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects. J Clin Pharmacol 48 (2008), 166–175.
34. Kay, K, Hastings, IM, Measuring windows of selection for anti-malarial drug treatments. Malar J, 14, 2015, 292.
35. Duru, V, Witkowski, B, Menard, D, Plasmodium falciparum resistance to artemisinin derivatives and piperaquine: a major challenge for malaria elimination in Cambodia. Am J Trop Med Hyg 95 (2016), 1228–1238.
36. Thanh, NV, Thuy-Nhien, N, Tuyen, NT, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin–piperaquine in the south of Vietnam. Malar J, 16, 2017, 27.
37. Leang, R, Canavati, SE, Khim, N, et al. Efficacy and safety of pyronaridine–artesunate for treatment of uncomplicated Plasmodium falciparum malaria in western Cambodia. Antimicrob Agents Chemother 60 (2016), 3884–3890.
38. Kabanywanyi, AM, Baiden, R, Ali, AM, et al. Multi-country evaluation of safety of dihydroartemisinin/piperaquine post-licensure in african public hospitals with electrocardiograms. PLoS One, 11, 2016, e0164851.
39. Plucinski, MM, Dimbu, PR, Macaia, AP, et al. Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015. Malar J, 16, 2017, 62.
40. Plucinski, MM, Talundzic, E, Morton, L, et al. Efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for treatment of uncomplicated malaria in children in Zaire and Uige Provinces, Angola. Antimicrob Agents Chemother 59 (2015), 437–443.